Evaluation of hyperpolarized [1-13C]-pyruvate by magnetic resonance to detect ionizing radiation effects in real time

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Sandulache, Vlad C ^a,b   Chen, Yunyun ^b   Lee, Jaehyuk ^b   Rubinstein, Ashley ^b   Ramirez, Marc S ^b   Skinner, Heath D ^b   Walker, Christopher M ^b   Williams, Michelle D ^b   Tailor, Ramesh ^b   Court, Laurence E ^b   Bankson, James A ^b   Lai, Stephen Y ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRUVIC ACID C 13; RADIOPHARMACEUTICAL AGENT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER TISSUE; CONTROLLED STUDY; HYPERPOLARIZED MAGNETIC RESONANCE SPECTROSCOPY; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MAGNETIC RESONANCE SPECTROSCOPIC IMAGING; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RADIATION DETECTION; RADIATION DOSE; RADIOSENSITIVITY; THYROID CARCINOMA; XENOGRAFT;

ANIMALS; CARBON ISOTOPES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLOW CYTOMETRY; FLUORESCEINS; HETEROGRAFTS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; OXIDATION-REDUCTION; PYRUVIC ACID; RADIATION, IONIZING; REACTIVE OXYGEN SPECIES; THYROID NEOPLASMS;

EID: 84899970457     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087031     Document Type: Article

References (43)

1. Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, et al. (2010) Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck 32: 829-836.
2. Derbel O, Limem S, Segura-Ferlay C, Lifante JC, Carrie C, et al. (2011) Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer 11: 469.
3. Forastiere AA, Trotti A, Pfister DG, Grandis JR (2006) Head and neck cancer: recent advances and new standards of care. J Clin Oncol 24: 2603-2605. (Pubitemid 46622079)
4. Smallridge RC, Copland JA (2010) Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 22: 486-497.
5. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, et al. (2009) Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab 94: 4423-4432.
6. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, et al. (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098. (Pubitemid 37464533)
7. Amosson CM, Teh BS, Van TJ, Uy N, Huang E, et al. (2003) Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique. Int J Radiat Oncol Biol Phys 56: 136-144. (Pubitemid 36403685)
8. Baujat B, Bourhis J, Blanchard P, Overgaard J, Ang KK, et al. (2010) Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev: CD002026.
9. Bernier J, Horiot JC (2012) Altered-fractionated radiotherapy in locally advanced head and neck cancer. Curr Opin Oncol 24: 223-228.
10. O'Sullivan B, Rumble RB, Warde P (2012) Intensity-modulated radiotherapy in the treatment of head and neck cancer. Clin Oncol (R Coll Radiol) 24: 474-487.
11. Staffurth J (2010) A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol) 22: 643-657.
12. Chen AP, Chu W, Gu YP, Cunnhingham CH (2013) Probing early tumor response to radiation therapy using hyperpolarized [1-(1)(3)C]pyruvate in MDA-MB-231 xenografts. PLoS One 8: e56551.
13. Nagaria P, Robert C, Rassool FV (2013) DNA double-strand break response in stem cells: mechanisms to maintain genomic integrity. Biochim Biophys Acta 1830: 2345-2353.
14. Pollycove M, Feinendegen LE (2003) Radiation-induced versus endogenous DNA damage: possible effect of inducible protective responses in mitigating endogenous damage. Hum Exp Toxicol 22: 290-306; discussion 307, 315-297, 319-223.
15. Sandulache VC, Skinner HD, Ow TJ, Zhang A, Xia X, et al. (2012) Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancer 118: 711-721.
16. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, et al. (2012) TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 18: 290-300.
17. de Oliveira MF, Amoedo ND, Rumjanek FD (2012) Energy and redox homeostasis in tumor cells. Int J Cell Biol 2012: 593838.
18. Gupta SC, Hevia D, Patchva S, Park B, Koh W, et al. (2012) Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 16: 1295-1322.
19. Sharma PK, Dwarakanath BS, Varshney R (2012) Radiosensitization by 2-deoxy-D-glucose and 6-aminonicotinamide involves activation of redox sensitive ASK1-JNK/p38MAPK signaling in head and neck cancer cells. Free Radic Biol Med 53: 1500-1513.
20. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR (2007) 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 67: 3364-3370. (Pubitemid 46724876)
21. Simons AL, Parsons AD, Foster KA, Orcutt KP, Fath MA, et al. (2009) Inhibition of glutathione and thioredoxin metabolism enhances sensitivity to perifosine in head and neck cancer cells. J Oncol 2009: 519563.
22. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, et al. (2003) Increase in signal-to-noise ratio of .10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A 100: 10158-10163. (Pubitemid 37071849)
23. Golman K, in 't Zandt R, Thaning M (2006) Real-time metabolic imaging. Proc Natl Acad Sci U S A 103: 11270-11275. (Pubitemid 44156508)
24. Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, et al. (2008) Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 68: 8607-8615.
25. Sandulache VC, Skinner HD, Wang Y, Chen Y, Dodge CT, et al. (2012) Glycolytic inhibition alters anaplastic thyroid carcinoma tumor metabolism and improves response to conventional chemotherapy and radiation. Mol Cancer Ther 11: 1373-1380.
26. Matsumoto S, Saito K, Yasui H, Morris HD, Munasinghe JP, et al. (2012) EPR oxygen imaging and hyperpolarized (13) C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate. Magn Reson Med.
27. Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, et al. (1996) Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 35: 103-111. (Pubitemid 26137174)
28. Sherman EJ, Lim SH, Ho AL, Ghossein RA, Fury MG, et al. (2011) Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol 101: 425-430.
29. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, et al. (2011) Assembly And Initial Characterization Of A Panel Of 85 Genomically Validated Cell Lines From Diverse Head And Neck Tumor Sites. Clin Cancer Res.
30. Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, et al. (2011) Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 17: 2281-2291.
31. Eruslanov E, Kusmartsev S (2010) Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol 594: 57-72.
32. Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, et al. (2011) Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer 117: 2926-2938.
33. Walker CM, Lee J, Ramirez MS, Schellingerhout D, Millward S, et al. (2013) A Catalyzing Phantom for Reproducible Dynamic Conversion of Hyperpolarized [1-13C]-pyruvate. PLoS One accepted for publication.
34. Harris T, Eliyahu G, Frydman L, Degani H (2009) Kinetics of hyperpolarized 13C1-pyruvate transport and metabolism in living human breast cancer cells. Proc Natl Acad Sci U S A 106: 18131-18136.
35. Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7: 91-101.
36. Bender K, Newsholme P, Brennan L, Maechler P (2006) The importance of redox shuttles to pancreatic beta-cell energy metabolism and function. Biochem Soc Trans 34: 811-814. (Pubitemid 44796427)
37. Pollak N, Dolle C, Ziegler M (2007) The power to reduce: pyridine nucleotides-small molecules with a multitude of functions. Biochem J 402: 205-218. (Pubitemid 46383418)
38. Tan C, Tuch BE, Tu J, Brown SA (2002) Role of NADH shuttles in glucose-induced insulin secretion from fetal beta-cells. Diabetes 51: 2989-2996.
39. Saito K, Matsumoto S, Devasahayam N, Subramanian S, Munasinghe JP, et al. (2012) Transient decrease in tumor oxygenation after intravenous administration of pyruvate. Magn Reson Med 67: 801-807.
40. Lee JH, Kim SY, Kil IS, Park JW (2007) Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP+-dependent isocitrate dehydrogenase. J Biol Chem 282: 13385-13394.
41. Simons AL, Fath MA, Mattson DM, Smith BJ, Walsh SA, et al. (2007) Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging. Int J Radiat Oncol Biol Phys 69: 1222-1230. (Pubitemid 47625869)
42. Thind K, Chen A, Friesen-Waldner L, Ouriadov A, Scholl TJ, et al. (2012) Detection of radiation-induced lung injury using hyperpolarized (13) C magnetic resonance spectroscopy and imaging. Magn Reson Med.
43. Yen YF, Nagasawa K, Nakada T (2011) Promising application of dynamic nuclear polarization for in vivo (13)C MR imaging. Magn Reson Med Sci 10: 211-217.